Advanced Prostate Cancer — Nivolumab With or Without Ipilimumab in Advanced Metastatic Cancer
Citation(s)
An Exploratory Study of Nivolumab With or Without Ipilimumab According to the Percentage of Tumoral CD8 Cells in Participants With Advanced Metastatic Cancer